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Abstract Since the late 1980s, intrathecal (IT) analgesic
therapy has improved, and implantable IT drug delivery
devices have become increasingly sophisticated. Physicians
and patients now have myriad more options for agents and
their combination, as well as for refining their delivery. As
recently as 2007, The Polyanalgesic Consensus Conference
of expert panelists updated its algorithm for drug selection
in IT polyanalgesia. We review this algorithm and the
emerging therapy included. This article provides an update
on newly approved as well as emerging IT agents and the
advances in technology for their delivery.
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Introduction
Since the late 1980s, intrathecal (IT) analgesic therapy has
increasingly become an accepted alternative to standard
medical management for the treatment of persistent pain
[1]. Because drug doses are much lower when applied
directly to the IT space compared with oral or parenteral
application, side effects and drug toxicities are often much
less. With the development of implantable IT drug delivery
devices, patients may benefit from continuous IT adminis-
tration of analgesics for years without fear of infection or
dislodgment. Newer sophisticated implanted IT drug
delivery systems and drug development allow clinicians to
further improve analgesia and limit adverse effects through
combination therapy and precise control over delivery [2•]
(Table 1). Clinicians may take advantage of the wide
variety of available agents and devices to tailor treatment
regimens to individual patients.
Three Polyanalgesic Consensus Conferences of expert
panelists have convened since 2000 for the purpose of
formulatinganalgorithmfordrugselectioninITpolyanalgesia.
These guidelines were published in 2000, 2003, and 2007 and
were based on “best evidence” and expert opinion, and
included guidelines for utilizing an IT drug selection algorithm
[2•, 3, 4], the results of surveys given to clinicians in the field
[2•], and directives for future studies [5].
This article provides an update on ziconotide, a recently
approved IT agent, as well as new and emerging agents.
New and emerging technology is also discussed.
First-Line Drugs: Morphine, Ziconotide,
Hydromorphone
The 2007 Polyanalgesic Consensus Conference labeled
morphine, ziconotide, and hydromorphone as first-line
therapy for IT application. Currently, only morphine and
ziconotide have approval from the US Food and Drug
Administration (FDA) for IT use. Hydromorphone has been
included as first-line therapy due to its widespread clinical
use and safety profile.
Ziconotide is an N-type calcium channel antagonist that
is effective for the treatment of neuropathic, nociceptive,
and mixed neuropathic/nociceptive pain. Ziconotide blocks
the N-type calcium channel located on the presynaptic
terminal of dorsal horn C fibers. By blocking calcium entry
into the presynaptic nerve terminal, ziconotide prevents the
release of neurotransmitters into the synapse. Morphine,
which acts on the µ-opioid receptor, is linked to this
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(Fig. 1). Whereas the inhibition of the N-type calcium
channel by ziconotide is direct, the inhibition of the calcium
channels by morphine is indirect and partial for several
reasons. First, not all µ receptors are linked to N-type
calcium channels. In addition, tolerance functionally
uncouples the µ receptor and the calcium channel. Due to
the direct action of ziconotide on the calcium channel,
tolerance does not occur [6]. Ziconotide is a nonopioid
analgesic approved by the FDA for IT delivery in 2004.
The efficacy of ziconotide in providing pain relief has been
demonstrated in several trials, prompting its addition to the
2007 Polyanalgesic Consensus Conference panel list of
level 1 drugs [2•, 7–10]. The panel recommended zicono-
tide as a viable alternative for patients who cannot tolerate
IT administration of morphine and/or hydromorphone [2•].
Ziconotide’s structure has implications for its therapeutic
use. It is relatively large compared with other analgesics
(eg, molecular weight is 2,639 Da compared with 285 Da
for morphine and 180 Da for aspirin); thus, diffusion is
relatively slower. At physiological pH, ziconotide is
permanently charged in contrast to other analgesics.
Permanently charged drugs penetrate into tissues slower
than drugs that alternate between charged and uncharged
forms at physiological pH. For example, morphine has one
ionizable amino group, so its freebase (neutral, uncharged)
form and its salt (positively charged)form are in equilibrium.
The freebase readily permeates hydrophobic tissue barriers,
and the salt readily diffuses in aqueous spaces of tissues.
Therefore, morphine distributes relatively efficiently into the
spinal cord and brain when administered orally or parenter-
ally. Three disulfide bonds wrap ziconotide into a molecular
ball. This and the modified N and C termini confer resistance
to cerebrospinal fluid (CSF) peptidases. Thus, clearance of
ziconotide from CSF is by the bulk flow of CSF, not by
metabolism in the CSF. The elimination half-life of IT
ziconotide from CSF in humans averaged 4.6 h. The
methionine amino acid is susceptible to oxidation by
molecular oxygen. Therefore, strategies to limit exposure
to oxygen are instituted. For example, the drug solution is
sparged with nitrogen (bubbled with N2 gas to drive off O2)
before the vial is capped for packaging, storage, and
shipping. Other drugs (eg, morphine, hydromorphone,
baclofen) can increase the rate of oxidation of ziconotide.
Oxidized ziconotide is less active than ziconotide, so a
pump containing a combination of ziconotide and another
medication may need to be refilled more often. For this
reason, the package insert for ziconotide does not recom-
Fig. 1 A nerve terminal of a primary afferent nociceptor is depicted,
which is stimulated by noxious stimuli in peripheral tissues such as the
skin or joints. Transmitters (eg, glutamate and substance P) released
from these neurons stimulate secondary neurons in the dorsal horn of
the spinal cord, which send the noxious signal to the brain. AP—
action potential. (Courtesy of Elan Corporation)
Table 1 2007 Polyanalgesic algorithm for intrathecal therapies
Treatment category Intrathecal drugs
First-Line drugs Morphine
Hydromorphone
Ziconotide
Second-Line drugs Fentanyl
Morphine/hydromorphone + ziconotide
Morphine/hydromorphone +
bupivacaine/clonidine
Third-Line drugs Clonidine
Morphine/hydromorphone/fentanyl/
bupivacaine + clonidine + ziconotide
Fourth-Line drugs Sufentanil
Sufentanil + bupivacaine +
clonidine + ziconotide
Fifth-Line drugs Ropivacaine
Buprenorphine
Midazolam
Meperidine
Ketorolac
Sixth-Line drugs Experimental agents
Gabapentin
Octreotide
Neostigmine
Adenosine
Xen2174
ZGK 160
(Data from Deer et al. [2•])
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However, a vast amount of clinical experience is surfacing on
the use of ziconotide in combination with a variety of drugs
with no adverse events reported. However, there are only two
publications on the combination of morphine and ziconotide.
In one study, ziconotide was added to morphine in 26 patients
on a stable IT morphine regimen [11]. There was a mean
14.5% reduction in pain and a 14.3% reduction in analgesic
use at week 5; however, response was highly variable. In a
second study, morphine was added to 25 patients on stable
IT ziconotide therapy [12]. This resulted in a mean 26.3%
reduction in pain and a 49.1% reduction in opioid
consumption at week 4. These studies suggest that there is
a synergism between morphine and ziconotide.
There were two initial double-blind, placebo-controlled
studies on ziconotide, one in malignant pain and one in
nonmalignant pain. Both studies were fast titration studies
with rapid increases in ziconotide dose over 5–10 days. The
studies resulted in dramatic percent changes in pain in
the ziconotide group over placebo (53.1% vs 18.1% in the
malignant study, and 31.2% vs 6% in the nonmalignant
study); however, in both studies there was a much higher
discontinuation rate in the ziconotide group [8, 10]. This
prompted a double-blind, placebo-controlled slow titration
study in which the ziconotide was titrated at a slower rate
over 3 weeks. Although the percent change in pain in the
ziconotide group versus placebo was not as dramatic
(14.4% vs 6.4%), it still reached statistical significance. In
addition, there was a much lower discontinuation rate and
better tolerability [7]. These studies demonstrated that
ziconotide has a dose-dependent effect, which can be
titrated to analgesia while minimizing side effects. In
addition, the studies also showed a significant effect on
the clinical global impression of pain control and satisfac-
tion, as well as a significant improvement in sleep.
Adverse reactions have not been reported following
accidental overdoses of ziconotide into the IT space or
tissue pocket as in overflow, system fracture, or pump miss
on refill [13]. IT ziconotide may be abruptly discontinued
without major withdrawal symptoms in patients who do not
tolerate the drug because of adverse effects [10]. However,
despite having demonstrated efficacy, ziconotide is associat-
ed with several adverse effects. The most frequent adverse
effects of IT ziconotide in descending order are memory
impairment, dizziness, nystagmus, speech disorder, nervous-
ness, somnolence, and abnormal gait [14]. Other adverse
effects reported in clinical trials and case studies include (but
are not limited to) elevated creatinine kinase levels, sedation,
nausea, headache, lightheadedness, depression, confusion,
ataxia, and emotional distress, with certain symptoms
possibly correlated with the rate of infusion [2•]. Although
some adverse effects correlate with infusion rate, they have
not been found to be dose-dependent [2•, 14]. Several cases
of accidental overdoses of ziconotide have occurred. In all
cases the patients had normal respirations and cardiovascular
function and recovered spontaneously [15].
IT ziconotide should be initiated at no more than 2.4 µg per
day (0.1 µg/hr) and titrated to patient response. The dosage
may be increased by up to 2.4 µg per day (0.1 µg/hr) at
i n t e r v a l sn om o r et h a nt w ot ot h r e et i m e sp e rw e e ku pt oa
recommended maximum of 19.2 µg per day (0.8 µg/hr). The
effective dose of ziconotide for analgesia is variable. The
package insert does not specify the length of titration. The full
analgesic effect of a new dose of ziconotide may not be fully
realized for several days following a dose change. Clinical
experience suggests that ziconotide should be started at a
lower dose than 2.4 µg per day, titrate the dose approximately
once per week, and use an overall titration period longer than
3 weeks. Faster titration is not recommended due to increased
adverse events and should only be used if there is an urgent
need for analgesia that outweighs the risk to patient safety.
Second- Through Fourth-Line Therapy: Fentanyl,
Bupivacaine, Clonidine, Sufentanil
Because of improved efficacy and reduced adverse effects
such as granuloma formation, fentanyl and drug mixtures,
including bupivacaine and clonidine, are second-line drugs;
clonidine as a single drug is third-line [13]. Sufentanil is
ranked fourth-line and has also been shown to reduce risk
of granuloma formation [13].
Clonidine binds to pre- and postsynaptic α2r e c e p t o r si n
the dorsal horn. Activation of these receptors depresses
presynaptive C-fiber transmitter release and hyperpolarizes
th epo st sy na pt i cme mb ra neth ro ug ht heGi -c ou pl edpo ta ss iu m
channel [16]. Clonidine is FDA approved for epidural use in
cancer pain only based on a large clinical trial in 85 cancer
patients [17]. However, it is most commonly used intrathe-
cally for the treatment of chronic neuropathic pain based on
extensive preclinical literature and clinical experience.
Clonidine is generally well tolerated, with hypotension,
bradycardia, and sedation occurring with overdose.
Bupivacaine is rarely used as a single agent and most
commonly used in combination with an opioid. Doses less
than 20 mg per day are generally well tolerated. Higher
doses usually result in tachyphylaxis and can lead to
sensory and motor disturbances, as well as urinary retention
and orthostatic hypotension [18].
Fentanyl and sufentanil are highly lipophilic µ-opioid
agonists. There are no reports or studies in the literature on
the use of fentanyl and sufentanil for chronic spinal drug
delivery. However, there is a lot of experience with the
acute delivery of these agents for postoperative and
obstetric pain. Fifteen micrograms of sufentanil delivered
acutely has been shown to be well tolerated with anesthetic
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phine and hydromorphone, which are highly hydrophilic,
fentanyl and sufentanil are highly lipophilic with a rapid
onset when delivered via acute blousing. This “kinetic-
based potency” makes these agents attractive when using
the Personal Therapy Manager or treating breakthrough
pain (see “Future Directions—New Technologies” for
discussion).
Fifth-Line Therapy: Ropivacaine, Buprenorphine,
Midazolam, Meperidine, Ketorolac
Buprenorphine is a partial µ-opioid receptor agonist and κ-
opioid receptor antagonist that improves pain when
administered intrathecally [20]. Although buprenorphine is
a partial µ agonist, its high affinity for the µ receptor leads
to a preferential agonist effect. Because it is an antagonist at
the κ receptor, it may minimize the dysphoric effects seen
with full agonists that reach the supraspinal regions [21].
Midazolam is a benzodiazepine-receptor agonist that is a
potential adjunctive therapy to ITopioid treatment. Preclinical
andclinicalinvestigationshavefoundmidazolamtocontribute
topainreductionwithoutmajoradverseeffects[22]. However,
rat studies reveal possible neurotoxicity [23]. Furthermore,
the commercially available formulation of midazolam avail-
able in the United States contains a preservative; therefore,
midazolam should not be used in patients with noncancer
pain unless they are at end of life [2•].
The cyclooxygenase (COX) inhibitor ketorolac has been
investigated for IT delivery with promising results. COX is
released at the spinal level in response to acute pain and
peripheral inflammation, contributing to central sensitiza-
tion [24]. Therefore, IT delivery of COX inhibitors
theoretically would reduce pain and central sensitization.
Animal data suggest that IT delivery of COX inhibitors can
do just that [24]. Safety studies in healthy volunteers have
not identified any adverse neurological or pain regulatory
effects [25, 26].
There are no studies or reports in the literature on the use
of ropivacaine and meperidine for IT delivery. However,
both agents have been used extensively for the treatment of
postoperative pain. Meperidine has been used via acute
blousing as an anesthetic agent with good tolerability [27].
Sixth-Line/Experimental Agents: Gabapentin,
Octreotide, Corpeptide, Neostigmine, Adenosine,
XEN2174, AM336, XEN, ZGX160
The potential to improve safety and efficacy of treatment
drives the development of new therapeutic agents. By
expanding the available choices of IT agents, clinicians are
afforded the opportunity to further individualize treatment
regimens to meet patient needs. However, until safety may
be thoroughly investigated, new agents should be used with
caution. Although not all FDA approved for IT administra-
tion, the agents categorized as first- through fifth-line are
generally accepted as safe and effective for IT use in cancer
and noncancer pain. Experimental agents should only be
used in terminal patients.
Gabapentin is a γ-aminobutyric acid analogue with FDA
approval for the treatment of epilepsy and postherpetic
neuralgia. Although gabapentin’s exact mechanism of
action is unknown, it is thought to bind to the α2δ subunit
of voltage-gated calcium channels resulting in the inhibition
of glutamate release in the spinal dorsal horn [28]o rt o
activate the noradrenergic system after nerve injury [2•, 29].
Gabapentin delivered intrathecally in various rat models of
pain demonstrate a very favorable analgesic profile [29].
Gabapentin has saturable transport both in the gut and at
the blood–brain barrier, making it a poor oral and systemic
agent [30]. Given the vast amount of preclinical studies
supporting a spinal mechanism together with its poor
absorption and blood–brain barrier penetration, the IT
delivery of gabapentin is very attractive. Gabapentin is
not yet FDA approved for IT use in humans; however, a
phase 2 trial is in progress.
Octreotide is a synthetic octapeptide of the growth
hormone somatostatin [31]. Because somatostatin is located
in the substantia gelatinosa and mitigates nociception,
octreotide has been investigated for similar effect. In a
preclinical study of rats with chronic constriction injury of
the sciatic nerve, IT octreotide reduced the behavioral
effects of thermal hyperalgesia [32]. In a dog model, IT
octreotide infusions of 40 µg per hour were not neurotoxic
[31]. Human use, though limited, has also not revealed
neurotoxicity. IT octreotide administered to patients with
cancer pain chronically over 5 years reduced pain without
adverse side effects [33]. One prospective, double-blind
human study of IT octreotide at doses of 405–650 µg per
day did not reveal any neurotoxicity or adverse side effects
[31]. However, a need for frequent pump refills may be
evidence of potential for tolerance [2•].
Adenosine is an endogenous purine nucleoside that
modulates many physiological processes, including those
in the heart and central nervous system. Adenosine is an
endogenous ligand that acts at four types of spinal receptors
to modulate pain transmission [34]. Animal models show
that systemic opioids increase spinal adenosine release [35].
IT adenosine does not inhibit acute pain [36] and has not
been found effective in reducing postoperative pain when
delivered 30 min prior to anesthesia [37]. Clinically, low-
dose IT adenosine is more effective at reducing allodynia
and hyperalgesia than spontaneous pain [38]. Increasing
evidence suggests that IT adenosine can be effective in the
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Although preclinical studies have not found adenosine to
be neurotoxic in rat spinal cord, further investigation into
adenosine’s neurotoxic profile is warranted before the drug
can be recommended for clinical use [2•].
Xen2174 is a chi-conopeptide derived from the venom
of the marine cone snail Conus marmoreus [42]. Like
tricyclic antidepressants, chi-conopeptides inhibit the nor-
epinephrine transporter [42], making them an attractive
potential treatment for chronic neuropathic pain. Unlike
tricyclic antidepressants, chi-conopeptides are highly selec-
tive for the norepinephrine transporter, and thus less likely
to cause side effects. A study in rats with either a chronic
constriction injury of the sciatic nerve or an L5/L6 spinal
nerve injury comparing Xen2174 with tricyclic antidepres-
sants and clonidine found IT Xen2174 to reduce allodynia
[43]. The antiallodynic, antihyperalgesic, and antinocicep-
tive effect of IT Xen2174 may be due to upregulation of
descending noradrenergic inhibition in the dorsal horn [42].
CGX-1160 is a conopeptide-based drug that produces
analgesia through activation of the neurotensin receptor
type 1 (NTR1) [42]. The mechanism of NTR1-induced
antinociception is unknown. The biotechnology company
Cognetix, Inc. has been developing CGX-1160 for IT use
and was granted an Orphan Drug designation for use in
neuropathic pain associated with spinal cord injury by the
FDA in 2005 [42]. A phase 1b clinical trial at Brigham and
Women’s Hospital in Boston found CGX-1160 to be safe
and effective for chronic intractable pain in a small group
spinal cord–injured patients [42].
Resiniferatoxin is an investigational drug that desensitizes
primarydorsalrootganglionneurons[44]. Resiniferatoxin is a
potent capsaicin analog that has been found to produce
analgesia in animal studies [44]. A phase 1, nonrandomized,
open-label, uncontrolled clinical trial of IT resiniferatoxin in
advanced cancer patients with severe pain is currently
underway to determine the effect of treatment in humans [45].
P-Saporin is a neurotoxin that selectively destroys cells
containing neurokinin-1 receptor neurons [46]. Because
neurokinin-1 receptor neurons transmit pain signals from
the spinal dorsal horn to the brain, their destruction
decreases pain signaling [46]. Animal studies have demon-
strated reduction in pain-related behaviors without long-
lasting toxicity or adverse effects [46, 47]. P-Saporin is
currently being evaluated for IT use in cancer patients with
chronic intractable pain [47].
Discussion on the Question of Efficacy of Chronic
Spinal Drugs
With the exception of ziconotide, there are no prospective
randomized controlled trials on the other agents used for
chronic IT therapy. From the reports in the literature, it is
difficult to draw conclusions on the efficacy of this therapy
due to many deficiencies, including 1) lack of psycholog-
ical assessment, 2) no mention of the methods used to
screen patients for responsiveness to intraspinal drug
therapy, 3) no control groups, randomization, or blinding,
4) no definition of the pain syndrome, 5) no standardization
of the methods used to assess outcome, 6) no standard
protocols for selecting, increasing, or changing the drug
used for intraspinal drug therapy, and 7) the studies to date
are short to intermediate follow-up. In all fairness, the
criticisms of these studies are inherent to the nature of
spinal drug delivery in that it is a highly invasive therapy
that makes it difficult to study using randomized controlled
trials.
One large study compared spinal drug delivery with
comprehensive medical management (CMM) of cancer
pain [48]. This study randomly assigned 202 patients to
an implantable drug delivery system (IDDS) or CMM.
Clinical success was defined as ≥ 20% reduction in pain
scores or equal scores with a ≥ 20% reduction in toxicity.
More IDDS patients achieved success and more IDDS
patients achieved ≥ 20% reduction in both pain and toxicity.
Although there was a nonsignificant change in mean pain
score between groups, the IDDS patients had a significantly
greater change in toxicity scores. IDDS patients also had
improved survival, with 53.9% survival at 6 months
compared with 37.2% in the CMM group.
Combination Spinal Drug Therapies
There are several persuasive reasons to assume that the
codelivery of agents with different mechanisms of action
may be therapeutically advantageous. First, many clinical
pain states are a composite of several mechanisms (eg,
acute afferent drive from the injured site that leads to a
persistent facilitated state and the expression of long-term
persistent changes in nervous system function after nerve
injury). In such states, it is reasonable to presume that an
agent with defined mechanisms of action may modulate one
component, but not all components of the systems that
underlie the specific pain state. Second, there is strong
evidence that the several agents may not display cross
tolerance (eg, µ and ∂ and µ and α2) and attenuate the
concurrent development of tolerance otherwise associated
with an equipotent dose of a single drug when given alone
[49]. Finally, even for pain states that are mediated by the
same mechanism, agents that act on different elements of
the systems may display nonlinear interactions that enhance
the therapeutic ratio. Numerous studies have emphasized
that spinally delivered agents may show positively syner-
gistic interactions with regard to modulation of nociceptive
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spinal µ and α2 agonists, enhanced nociception can result
without an attendant increasing respiratory depression or
hypotension [51].
Given the numerous pain pathways located in the dorsal
horn cells (various receptor systems and ion channels),
spinal drug delivery lends itself to a vast improvement in
efficacy and tolerability. Clinical experience has supported
this observation, as combination therapy is widely used.
Although there is a vast amount of literature on the safety
of single agents in animal toxicity studies, there is none on
the safety of drug combinations. An extensive discussion of
safety evaluation for spinally delivered drugs can be found
elsewhere [52]. The increased use of IT drug combinations
has led to a proliferation of compounding pharmacists used
to prepare such mixtures. In addition, this has led to the
frequent use of higher concentrations of drugs to increase
the time between pump refills, which has led to increasing
reports of catheter tip granuloma formation (see discussion
below). When using higher concentrations, close observa-
tion of the patient is required with documentation of a
detailed neurological examination and attention to new
neurological symptoms or increase in pain. Also, close
communication between the compounding pharmacist and
physician is necessary. The physician’s role is to monitor
the patient for efficacy, safety, and tolerability, while the
compounding pharmacist must evaluate the mixtures for
pyrogenicity and solubility. Close communication between
the physician and pharmacist as well as close monitoring of
the patient can provide the patient with the vast benefits of
drug combination therapy.
Future Directions—New Technology
New IT technologies aim to improve both safety and
efficacy. IT drug delivery devices are becoming increas-
ingly compatible with agents and admixtures. Programma-
ble delivery systems have also been evolving to address the
intra-and inter-patient pain variability. Technology that can
effectively and safely treat breakthrough pain is a continued
goal. As programming technology advances, however,
space for infusate storage decreases and implantable pumps
become more bulky. Increased power requirements from
bolus options and programming features also limit battery
life, necessitating more frequent surgical battery exchange.
Pumps that require less energy and rechargeable systems
are a relatively new approach to this problem. A piezoelec-
tric membrane pump has been developed that reduces both
bulk and energy requirement [53]. Technology behind
rechargeable spinal cord stimulators may be eventually
applied to IT pumps [13]. Finally, less fragile pump
materials may have a future in reducing drug delivery
system damage, breakdown, and failure [13]. By broaden-
ing the available options of drug delivery, innovations in IT
therapy may reach new subsets of patients.
A number of new pump systems have recently been
developed to improve IT delivery. The Prometra Program-
mable Pump System (InSet Technologies, Inc., Mount
Olive, NJ) is an investigational, fully implantable device
designed to improve precision in drug delivery. The system
utilizes a positive pressure design with gate-controlled
administration of morphine into the 20-mL fixed-volume
control chamber to ensure dosing accuracy [54]. This
system allows a flow rate of up to 28 mL per day. It
weighs 150 g, has a diameter of 71 mm, is 20 mm thick,
and is comprised of highly durable, mostly immobile parts
to promote usage for more than 10 years [54]. A clinical
trial of the Prometra pump conducted in individuals with
intractable chronic cancer pain or chronic nonmalignant
pain demonstrated an overall 97.5% dose accuracy rate
[55–57] and statistically significant improvements in visual
analogue scale score, numeric rating scale score, and
Oswestry disability index assessments from baseline to
1 year [58]. FDA approval of the Prometra pump is
expected shortly based on the pump’s ability to achieve
preestablished end points for accuracy, efficacy, and safety
at desirable flow rates.
The MedStream Programmable Infusion System (Codman
and Shurtleff, Inc., a Johnson & Johnson Co., Raynham,
MA) is another implantable device currently under inves-
tigation. This implantable drug delivery system offers
improved catheter technology and pump durability. Its
SureStream intraspinal catheter has been designed to resist
kinking and tearing. The MedStream ceramic drive system
maintains the infusion rate without motors, gears, or
rotating parts [59].The pump has either a 20- or 40-mL
reservoir, and measures 76 mm by 21.6 mm (20 mL) or
28.2 mm (40 mL) [59]. The MedStream is currently pending
FDA approval, although it is available for sale in several
European countries [59].
The Medallion (Advanced Bionics, Valencia, CA) is an
implantable drug delivery system awaiting FDA approval
for study in humans. The Medallion system focuses on
safety improvements with the creation of a negative
pressure reservoir. Should a break in the system occur,
medication would not leak out of the reservoir into the
body. Furthermore, the negative pressure draws medication
from the syringe during pump refills rather than requiring
syringe plunger manipulation [60]. A pressure sensor is
present to detect flow resistance. The Medallion, with either
a 20- or 40-mL pump, measures 2.6 in. in diameter and is
0.72 in. thick across the flat portion of the can [60]. Both
sizes include a sutureless connector, a radio-opaque IT
catheter, and are compatible with an 8-year battery at
0.5 mL per day [60]. The Medallion clinical trials will
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overall safety and efficacy of the device [60].
The Personal Therapy Manager (PTM, Medtronic, Inc.,
Minneapolis, MN) is a compatible handheld device to be
used with an existing IT drug delivery system. This
technology is designed to address breakthrough pain by
allowing patients to self-administer a bolus dose of infusate.
The PTM was approved by the FDA in 2005 for
concomitant use with the SynchroMed II pump [61].
Maximum bolus dosing is specified in order to avoid
administrative overdose. The device also records usage,
pre- and post-bolus pain scores, and technical events, as
well as calculates predicted refill requirements based on
background infusion and bolus doses [13, 62, 63]. Patients
using the device have reportedly experienced a 29%
reduction in pain, improved quality of life, and reduced
need for supplemental analgesics, and there have been no
reported major adverse events associated with its use [62].
The PTM is only compatible with the newer SynchroMed
pumps and is not covered by many managed care
organizations or Medicare. The out-of-pocket cost for
patients is estimated at $500.
Concerns
As recently described by Coffey et al. [64], IT opioid drug
infusion is not a completely harmless technique. They
found higher than expected mortality among noncancer
pain patients treated with IT opioid infusion attributable to
inadvertent drug overdose. Incorrect programming, pump
malfunction or fracture, and complications with pump refill
all pose risk of drug overdose. Likewise, abrupt withdrawal
or otherwise improper dose titration is a potential adverse
outcome of improper system management.
Patient characteristics may also increase complication
risk and interfere with IT drug delivery. Myriad comorbid-
ities, including systemic infection risks, skin breakdown or
localized infection, spinal metastatic disease, bleeding
diathesis, poor nutritional status, or severe psychiatric
disturbance may make IT therapy undesirable and even
unsafe. IT drug delivery in noncancer patients or nonter-
minal cancer patients has potential for greater complication
risk simply due to length of treatment. As new technology
and pharmaceutical options arise, clinicians must continue
to exert care over patient selection.
Catheter-tip granulomas are another potential source
of adverse outcome with IT drug delivery. IT inflamma-
tory masses are relatively common. Sixty-three percent
of responding physicians recently polled in an online
survey reported experience with granulomas in their
patients [2•]. All agents used in implantable infusion
systems except fentanyl and sufentanil have been associ-
ated with granuloma formation [2•]. Clinical research
suggests that dose escalation and increases in concentra-
tion can prompt the development of IT granulomas.
Although usually innocuous, IT granulomas may lead to
catastrophic neurologic dysfunction and permanent paral-
ysis [65]. Signs suggestive of granuloma formation
include loss of analgesic effect and new and progressive
neurologic symptoms [66]. Small granulomas that are
identified early require only minimally invasive therapy
such as cessation of drug administration through the
affected catheter and awaiting gradual granuloma shrink-
age, whereas larger masses require surgical removal [66].
Vigilant monitoring for signs of possible inflammatory
mass formation will assist in early diagnosis, and may
avoid surgical removal and neurologic damage. When
possible, catheter tip placement in the lumbar thecal sac
and use of lowest possible opioid doses will lower the risk
of granuloma formation [66].
Finally, surgical complications such as infection and
bleeding pose risk of complications. There are no controlled
trials on surgical implantation technique [13]. Future
investigation into optimal perioperative care, percutaneous
approach, and surgical technique to improve outcome and
reduce complications is warranted.
Conclusions
Since the first clinical implant of an infusion pump IT drug
delivery to treat chronic pain, there have only been two
agents that have achieved FDA approval. If IT therapy were
to be limited to these two agents, the efficacy of this
therapy would be inadequate. Therefore, the vast majority
of the clinical experience has been with the off-label use of
a variety of agents with different mechanisms of action.
This has led to the widespread use of this therapy to treat
both cancer and noncancer pain. The success of the clinical
trials with ziconotide demonstrate that this therapy can be
studied using randomized controlled trials. Hopefully, this
will open the door for more agents to reach the market such
as gabapentin, which is currently in phase 2 trials.
There remains a lot unknown about IT therapy for the
treatment of chronic pain. The delivery methods for IT
therapy are fairly straightforward; however, the pharmacol-
ogy is quite complex. The polyanalgesic consensus panel
has provided detailed guidance over the past decade. Future
directions should focus on gathering data on the efficacy
and safety of this therapy. Given the complexities and costs
of randomized controlled trials in the area of pain medicine,
large multicenter registries are probably the best way of
achieving this goal. Until this is achieved, physicians will
continue to rely on guidelines created from limited data and
their own clinical experience.
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